Remedy’s investor relations are coordinated by the Chief Executive Officer.

Investor meetings and statements issued by the company are subject to a silent period of 30 days preceding the publication of a business review, a half-year review or a financial statements release.

Tero Virtala
Chief Executive Officer
+358 9 435 5040

General requests